Changing to Avastin could save NHS £100m a year
Posted on 25th November 2014
The drug Avastin has been in the newscalling for its use in the UK in a bid to save millions each year.
Popular in the US, Avastin is used for patients with age-related macular degeneration (AMD). It has been on the market for years, gone through all the testing and has been proven to be as effective as Lucentis, the NHS approved drug for the same condition. The difference is cost. Lucentis typically costs around £700 per treatment, compared to Avastin which is about £70. Yet red tape seems to be halting its use.
It is currently unlicensed in the UK so should anything go wrong with its use, the practitioner may not be legally covered. However, in times of austerity and it is perhaps time for the NHS to move forward and license its use.
Related Posts
COVID-19 advice
28th April 2021
This page will have our latest information on the care we can provide during the COVID-19 pandemic. You can also find information on our Facebook page. LATEST UPDATE: Weds, 28 Apr 2021 We are opera...
Read more
Rebecca first to obtain new glaucoma qualification
22nd April 2021
After a year like no other, we are especially impressed by our optometrist, Rebecca Daly, who is one of the first individuals to have gained the NHS Education for Scotland Glaucoma Award Training (NES...
Read more
New treatment launches to slow the increasing myopia epidemic
14th April 2021
Myopia is expected to affect 50% of the world population by 2050. In the UK, the amount of myopia has increased from 10% to 23% of children in the past 50 years. In the past year, we have noticed an i...
Read more
Worried about your child’s eyesight?
08th March 2021
When most of us were growing up, it was simply a case of whether a child needed glasses or not. A short-sighted (myopic) child would be prescribed glasses, and each year they would likely require a st...
Read more